We work on developing gene therapies for congenital and early onset muscular dystrophies and neuromuscular disorders. And to accomplish this, we use different gene therapy modalities to address the underlying genetic causes of those disorders. The continuous development of viral and non-viral gene therapy vectors has been very important to our field.
As the new improved viral and non-viral gene therapy vectors allow safer and more efficient gene therapies to be developed, this in turn enhances the safety and reduces the time to get those therapies ready for the patients. In this protocol, we provide thorough and detailed optimized steps of performing mouse lateral tail vein injections, and the aim of this protocol is to assist experimenters in consistently performing the injection procedures successfully.